Rare Inflammatory Disease Treatment Market by Indication (Ulcerative Colitis, Juvenile Rheumatoid Arthritis, Psoriatic Arthritis and Other Indications), Drug Class (Biologics and Organic Compounds), Mode of Administration (Injectable, Oral and Others), Distribution Channel and Region Forecast- 2022-2028
Rare Inflammatory Disease Treatment Market by Indication, Drug Class, Mode of Administration, End User & Region - Forecast to 2022 – 2028: Analysis and Review
- December 2021
- 170 pages
Rare Inflammatory Disease Treatment Market Outlook (2022-2028)
[170 Pages Report] The Rare Inflammatory Disease Treatment Market has garnered a market value of US$ 12,664 Mn in 2021, anticipated to register a positive CAGR of 4.6% in the forecast period 2022-2028 and reach a value of US$ 17,335.8 Mn.
Rare Inflammatory Disease Treatment Market Size (2022)
US$ 13,249.2 Mn
Projected Market Value (2028)
US$ 17,335.8 Mn
Global Market Growth Rate (2022-2028)
Region With Dominant Market Share
Increasing investment in R&D for various drug developments and increasing demand for different modes of drug administration have further boosted the market demand for various rare inflammatory diseases treatments.
Industry Analysis of Rare Inflammatory Disease Treatment (2013 to 2021) Vs Market Estimates (2022 to 2028)
From 2013 to 2021, treatment for rare inflammatory diseases experienced an increase of 3.8% in value CAGR terms. Various distribution channels such as hospital pharmacies, retail pharmacies, and online pharmacies have observed high demand for treating several rare inflammatory diseases. Recent outbreaks of infectious diseases, such as COVID-19, have increased market demand to a major extent.
During the height of the pandemic crisis, clinicians, doctors and other healthcare stakeholders extensively relied on anti-inflammatory drugs to ease complications experienced by severely infected and immunocompromised patients. Drugs such as ibuprofen, for instance, was cleared by the National Health Service in the U.K to be used as a nonsteroidal anti-inflammatory drug (NSAID) to inhibit receptors responsible for triggering an inflammatory response to the coronavirus.
Companies have been considering in their production processes ways to improve the treatment of rare inflammatory diseases, such as eosinophilic granulomatosis with polyangiitis (EGPA), a rare disorder that causes vasculitis. One such treatment is Nucala, a medication for patients aged 6 years or older with relapsing-remitting or refractory EGPA. Likewise, several orphan drugs are coming into the limelight for numerous rare inflammatory diseases. Overall, demand for rare inflammatory disease treatment is anticipated to rise at a CAGR of around 4.6% through 2028.
How is the Rising Incidence of Inflammatory & Autoimmune Diseases Generating Opportunities for New Therapies?
Healthcare experts have associated cytokine IL-23 with treatment of inflammatory and autoimmune diseases. Researchers have identified a fundamental molecular mechanism essential to inflammatory and autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and psoriasis. The action of pro-inflammatory cytokine IL-23, depends on the organizational stimulation of its receptor, namely IL-23R.
Moreover, the occurrence of inflammatory and autoimmune diseases is increasing at a rapid pace. According to the World Health Organization, psoriasis affects approximately 100 million people globally, while between 1.3% and 34.7% develop chronic and inflammatory arthritis. Likewise, inflammatory bowel infections such as ulcerative colitis and Crohn’s disease are increasing at an alarming rate in formerly unaffected fragments of the world.
Hence, medical practitioners are introducing several drug candidates to address some of the most debilitating rare inflammatory diseases. In 2018, for instance, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) granted an extension of indication to Kineret (anakinra) for treating Still's disease. Kineret is an immunosuppressive medicine which inhibits chemical messenger activity of interleukin-1, an agent which is produced in excess amongst patients suffering from rheumatoid arthritis and juvenile idiopathic arthritis.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
High Prevalence Rate amongst Adults & Children Broadening Prospects in North America?
FMI forecasts the rare inflammatory disease treatment industry in North America to accumulate a market share of 39.9% in 2022. The presence of a well-developed health care system and several reimbursement programs aimed at facilitating access to treatment for those with rare illnesses are among the chief growth drivers.
More than 30 million Americans are afflicted with rare diseases. Every year, approximately 6,200 Americans are affected diseases, including Polycythemia Vera, while juvenile rheumatoid arthritis is one of the most common types of arthritic diseases that children are diagnosed with in the United States.
Demand for rare inflammatory disease treatment has risen through various distribution channels including hospital pharmacies, retail pharmacies, and online pharmacies. As a result, the U.S. is expected to account for the largest market share in the market for rare inflammatory diseases treatment.
How is Discovery of New Add-On Treatments Facilitating Expansion in Europe?
D of new treatments and advancements in medical technology have driven market demand for rare inflammatory disease treatment throughout Europe. With increasing investments in open-source drug delivery systems and evaluations of their effectiveness in treating rare diseases, more treatment options are becoming available for rare inflammatory diseases.
Recently, in September 2021, the European Medicines Agency has recommended granting an extension of indication to Nucala (mepolizumab) as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA), responsible for inflaming vital organs such as the lungs, heart, skin, nervous system and gastrointestinal tract.
It is estimated that between 0.18 and 4 new cases per 1 million are diagnosed each year with EGPA. The drug is already approved for treating patients of the same age group for eosinophilic asthma. According to FMI, rare inflammatory disease treatment in Europe is like to accumulate a market share of 24% in 2022.
Rare Inflammatory Disease Treatment Market - Category-wise Analysis
Will Ulcerative Colitis Spearhead Rare Inflammatory Disease Treatment Demand?
Due to the significant cost savings associated with ulcerative colitis treatments, the producers will be influenced to increase their manufacturing capacities for advanced drugs and therapies in the future.
Technological advancements and the increasing number of patients suffering from ulcerative colitis have contributed to the development of advanced treatments for ulcerative colitis. The influx of new therapeutics methods, demand for enhancing drugs, and advances in treating ulcerative colitis have propelled market demand for rare inflammatory diseases treatments.
Why are Retail Pharmacies Emerging as the Primary POC for Availing Rare Inflammatory Disease Treatment Drugs?
The growing prevalence of diseases and demand for 24/7 medication sales have catalyzed the global market demand for drugs at retail pharmacies. Future growth in artificial intelligence, advanced analytics, and other technologies will help drive the retail pharmacy market in the global market.
Health and wellness services are the key drivers of customer satisfaction at brick-and-mortar pharmacies. These services score 66 points higher than other types of services. Pharmacies with these services are present in 86% of chain pharmacies, 83% of supermarkets, and 75% of mass merchandisers.
Rare Inflammatory Disease Treatment Market - Competitive Landscape
Prominent treatment providers are emphasizing on advancing drug and treatment offerings by initiating a series of clinical studies as well as forging collaborative and acquisition agreements with existing pharmaceutical companies.
- In December 2021, Pfizer Inc. announced that it had reached a definitive agreement to acquire Arena Pharmaceuticals Inc., which is developing innovative possible treatments for a variety of immuno-inflammatory diseases. The proposed acquisition offers best-in-class treatment to address unmet clinical needs for more patients with immuno-inflammatory diseases
- Likewise, in November 2021, Regeneron Pharmaceuticals Inc. announced additional positive results from a Phase 3 trial run jointly with NIAID on the use of single dose of investigational REGEN-COV® 1,200 mg sub-cutaneous injections. The findings revealed that the drug successfully protects healthy individuals from contracting COVID-19 with a success rate of 81.6%
Rare Inflammatory Disease Treatment Report Scope
Historical Data Available for
US$ Mn for Value
Key Regions Covered
Key Countries Covered
Key Market Segments Covered
Key Companies Profiled
Available upon Request
Key Segments Covered in Rare Inflammatory Disease Treatment Industry Survey
Rare Inflammatory Disease Treatment by Indication
- RID Treatment for Ulcerative Colitis
- RID Treatment Juvenile Rheumatoid Arthritis
- RID Treatment Psoriatic Arthritis
- RID Treatment Other Indications
Rare Inflammatory Disease Treatment by Drug Class
- Biologics-based RID Treatment
- Organic Compounds-based RID Treatment
Rare Inflammatory Disease Treatment by Mode of Administration
- RID Injectables
- Oral RID Treatment
- Other RID Treatment Administration Modes
Rare Inflammatory Disease Treatment by Distribution Channel
- RID Treatment through Hospital Pharmacies
- RID Treatment through Retail Pharmacies
- RID Treatment through Online Pharmacies
Rare Inflammatory Disease Treatment Market by Region
- North America RID Treatment Market
- Latin America RID Treatment Market
- Europe RID Treatment Market
- Asia Pacific RID Treatment Market
- Middle East & Africa (MEA)